Your browser doesn't support javascript.
loading
Pulmonary Hypertension in Children with Down Syndrome: Results from the Pediatric Pulmonary Hypertension Network Registry.
Hopper, Rachel K; Abman, Steven H; Elia, Eleni G; Avitabile, Catherine M; Yung, Delphine; Mullen, Mary P; Austin, Eric D; Bates, Angela; Handler, Stephanie S; Feinstein, Jeffrey A; Ivy, D Dunbar; Kinsella, John P; Mandl, Kenneth D; Raj, J Usha; Sleeper, Lynn A.
Afiliação
  • Hopper RK; Department of Pediatrics, Stanford University School of Medicine, Lucile Packard Children's Hospital Stanford, Palo Alto, CA. Electronic address: rhopper@stanford.edu.
  • Abman SH; Pediatric Heart Lung Center, Department of Pediatrics, University of Colorado Denver Anschutz Medical Center and Children's Hospital Colorado, Aurora, CO.
  • Elia EG; Department of Cardiology, Boston Children's Hospital, Boston, MA.
  • Avitabile CM; Division of Cardiology, Children's Hospital of Philadelphia, Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
  • Yung D; Division of Pediatric Cardiology, Department of Pediatrics, University of Washington and Seattle Children's Hospital, Seattle, WA.
  • Mullen MP; Department of Cardiology, Boston Children's Hospital, Boston, MA; Department of Pediatrics, Harvard Medical School, Boston, MA.
  • Austin ED; Department of Pediatrics, Vanderbilt University Medical Center, Monroe Carell Jr Children's Hospital, Nashville, TN.
  • Bates A; Division of Cardiology, Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada.
  • Handler SS; Division of Cardiology, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI.
  • Feinstein JA; Department of Pediatrics, Stanford University School of Medicine, Lucile Packard Children's Hospital Stanford, Palo Alto, CA.
  • Ivy DD; Division of Cardiology, Department of Pediatrics, University of Colorado Denver Anschutz Medical Center and Children's Hospital Colorado, Aurora, CO.
  • Kinsella JP; Division of Neonatology, Department of Pediatrics, University of Colorado Denver Anschutz Medical Center and Children's Hospital Colorado, Aurora, CO.
  • Mandl KD; Computational Health Informatics Program, Boston Children's Hospital, Departments of Pediatrics and Biomedical Informatics, Harvard Medical School, Boston, MA.
  • Raj JU; Department of Pediatrics, University of Illinois at Chicago, Chicago, IL.
  • Sleeper LA; Department of Cardiology, Boston Children's Hospital, Boston, MA; Department of Pediatrics, Harvard Medical School, Boston, MA.
J Pediatr ; 252: 131-140.e3, 2023 01.
Article em En | MEDLINE | ID: mdl-36027975
OBJECTIVE: To characterize distinct comorbidities, outcomes, and treatment patterns in children with Down syndrome and pulmonary hypertension in a large, multicenter pediatric pulmonary hypertension registry. STUDY DESIGN: We analyzed data from the Pediatric Pulmonary Hypertension Network (PPHNet) Registry, comparing demographic and clinical characteristics of children with Down syndrome and children without Down syndrome. We examined factors associated with pulmonary hypertension resolution and a composite outcome of pulmonary hypertension severity in the cohort with Down syndrome. RESULTS: Of 1475 pediatric patients with pulmonary hypertension, 158 (11%) had Down syndrome. The median age at diagnosis of pulmonary hypertension in patients with Down syndrome was 0.49 year (IQR, 0.21-1.77 years), similar to that in patients without Down syndrome. There was no difference in rates of cardiac catheterization and prescribed pulmonary hypertension medications in children with Down syndrome and those without Down syndrome. Comorbidities in Down syndrome included congenital heart disease (95%; repaired in 68%), sleep apnea (56%), prematurity (49%), recurrent respiratory exacerbations (35%), gastroesophageal reflux (38%), and aspiration (31%). Pulmonary hypertension resolved in 43% after 3 years, associated with a diagnosis of pulmonary hypertension at age <6 months (54% vs 29%; P = .002) and a pretricuspid shunt (65% vs 38%; P = .02). Five-year transplantation-free survival was 88% (95% CI, 80%-97%). Tracheostomy (hazard ratio [HR], 3.29; 95% CI, 1.61-6.69) and reflux medication use (HR, 2.08; 95% CI, 1.11-3.90) were independently associated with a composite outcome of severe pulmonary hypertension. CONCLUSIONS: Despite high rates of cardiac and respiratory comorbidities that influence the severity of pulmonary hypertension, children with Down syndrome-associated pulmonary hypertension generally have a survival rate similar to that of children with non-Down syndrome-associated pulmonary hypertension. Resolution of pulmonary hypertension is common but reduced in children with complicated respiratory comorbidities.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Refluxo Gastroesofágico / Síndrome de Down / Cardiopatias Congênitas / Hipertensão Pulmonar Tipo de estudo: Clinical_trials Limite: Child / Humans / Infant Idioma: En Revista: J Pediatr Ano de publicação: 2023 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Refluxo Gastroesofágico / Síndrome de Down / Cardiopatias Congênitas / Hipertensão Pulmonar Tipo de estudo: Clinical_trials Limite: Child / Humans / Infant Idioma: En Revista: J Pediatr Ano de publicação: 2023 Tipo de documento: Article País de publicação: Estados Unidos